Recombinant collagen-hyaluronic acid compound and preparation method thereof
By designing the covalent coupling of recombinant collagen and hyaluronic acid, a complex with amide bonding is formed, which solves the problem of easy degradation of collagen and hyaluronic acid, significantly improves the skin's moisturizing and elasticity, and It extends its time to act in the skin and is suitable for the medical beauty field.
Patent Information
- Application Number
- CN202411164284.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The existing collagen and hyaluronic acid as natural facial fillers have problems such as easy degradation, short retention time in vivo and biological toxicity, and traditional collagen has problems such as animal-derived pathogens and unstable purity.
By designing the optimized covalent coupling of recombinant collagen and hyaluronic acid, γ-polyglutamic acid is used as a biological scaffold material to form a complex with amide bonding, enhancing its biocompatibility and mechanical properties and slowing down degradation rate.
It significantly improves the moisturizing and natural elasticity of the skin, extends the effective time of action in the skin, optimizes biocompatibility and stability, and is suitable for supporting materials in the medical and beauty field.
Smart Images

Figure CN119015506A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioengineering, and in particular relates to a recombinant collagen-hyaluronic acid complex and a preparation method thereof. Background Art
[0002] Skin fillers are a common treatment method in cosmetic medicine, which aims to improve the appearance of the skin, reduce wrinkles and fine lines, restore facial volume or improve facial contours. Commonly used filler materials include hyaluronic acid (HA), calcium hydroxyapatite, poly-L-lactic acid and collagen. Among them, collagen, as a natural facial filler material, is an abundant structural protein in the human body, known for its excellent biocompatibility, safety and key role in tissue health and function. Collagen is divided into animal-derived and recombinantly expressed. Traditional animal or human-derived collagen has the risks of animal-derived pathogens and immune responses, as well as low purity and unstable quality. The basic structural unit of collagen is a triple helix structure formed by three polypeptide chains entangled. Each chain contains a repeated Gly-XY amino acid sequence. These chains form a stable triple helix structure through hydrogen bonds during the synthesis process, where Gly is glycine, and X and Y are usually proline and hydroxyproline. While recombinant collagen has high biocompatibility and safety, it also faces high costs and technical challenges in purification and expression, and cannot completely simulate the effects of natural collagen.
[0003] As a natural facial filler, hyaluronic acid (HA) is a linear polysaccharide composed of repeated N-acetylglucosamine and glucuronic acid units. It has high hydration and biocompatibility, but is easily degraded by hyaluronidase in the body and needs to be frequently supplemented to maintain the effect. In addition, when hyaluronic acid is used as a facial filler, its support is poor, which affects the long-term effect. To solve these problems, researchers have explored the cross-linking technology of collagen and hyaluronic acid in order to combine the advantages of both. However, the use of chemical cross-linking agents such as glutaraldehyde, although effective cross-linking, may bring potential toxicity, leading to cytotoxicity and inflammatory response. Although the physical cross-linking method can avoid chemical toxicity, its cross-linking structure is usually weak, resulting in poor stability in the body, and further optimization is still needed to meet clinical needs. For this reason, the present invention proposes a recombinant collagen-hyaluronic acid complex and a preparation method thereof. Summary of the invention
[0004] The object of the present invention is to provide a recombinant collagen-hyaluronic acid complex and a preparation method thereof, aiming to solve the problems raised in the above background technology.
[0005] To achieve the above object, the present invention provides the following technical solutions:
[0006] A recombinant collagen-hyaluronic acid complex, wherein the recombinant collagen has a triple helix structure, and the hyaluronic acid is coupled with the recombinant collagen through a covalent bond to form a complex.
[0007] Furthermore, the structural formula of the recombinant collagen-hyaluronic acid complex is as follows:
[0008]
[0009] Furthermore, the recombinant collagen is an optimized recombinant human type III collagen, and the amino acid sequence of the recombinant collagen obtained by algorithm design and optimization screening is shown in SEQ ID No. 1. The molecular weight of the recombinant collagen is selected to be 50-200 kDa, preferably 50-150 kDa, and more preferably 100 kDa.
[0010] Furthermore, the components of the recombinant collagen-hyaluronic acid complex include γ-polyglutamic acid (γ-PGA) with a molecular weight of 700 kDa.
[0011] The carboxyl group (-COOH) of recombinant collagen undergoes esterification reaction with the hydroxyl group (-OH) of hyaluronic acid, and γ-PGA, as a biological scaffold material, provides carboxyl groups (-COOH) to undergo amidation reaction and cross-linking with the amine group (-NH2) of recombinant collagen to form an amide bond (-CONH) that is highly resistant to enzyme degradation in the human body, thereby slowing down the degradation rate. A recombinant collagen-hyaluronic acid complex with better biocompatibility, high stability and mechanical properties is formed.
[0012] According to the use of the recombinant collagen-hyaluronic acid complex described above in the preparation of tissue engineering materials.
[0013] A method for preparing the recombinant collagen-hyaluronic acid complex according to the above-mentioned method comprises the following steps:
[0014] Step 1: dissolving the recombinant collagen in 10-100 mM MES buffer prepared with water for injection, and adding γ-PGA to the solution to form a first composite system;
[0015] Step 2: mixing the first composite system with the first cross-linking agent to form a first cross-linking system;
[0016] Step 3: mixing the first cross-linking system with the second cross-linking agent to obtain a collagen-scaffold cross-linking system; the second cross-linking agent is different from the first cross-linking agent;
[0017] Step 4: Mix hyaluronic acid with the collagen-scaffold cross-linking system to obtain a recombinant collagen-hyaluronic acid complex. Then, mix the recombinant collagen-hyaluronic acid complex in a 2-(N-methylamino)ethanesulfonic acid (MES) buffer.
[0018] Furthermore, the biological scaffold material can be dimethyl glutarate, polylysine, chitosan, alginate, γ-PGA, polyethylene glycol or uronic acid, preferably γ-PGA, with a molecular weight of 700 kDa.
[0019] Further, hyaluronic acid can be low molecular weight hyaluronic acid, medium molecular weight hyaluronic acid, high molecular weight hyaluronic acid, ultra-high molecular weight hyaluronic acid, cross-linked hyaluronic acid, hydrolyzed hyaluronic acid, acetylated hyaluronic acid or sodium hyaluronic acid. After hyaluronic acid is cross-linked with recombinant collagen, a stable three-dimensional network structure can be formed, providing better mechanical strength and elasticity. Low molecular weight hyaluronic acid can effectively fill the gap between collagen during cross-linking, strengthen the overall stability and durability of the material, and hyaluronic acid has good sustained release properties, and low molecular weight hyaluronic acid can gradually release active ingredients after cross-linking with collagen, extending its action time in the skin. Therefore, preferably low molecular weight hyaluronic acid, it is selected as 5-200kDa, preferably 20-100kDa, more preferably 50kDa, 70kDa.
[0020] Furthermore, the first crosslinking agent can be an aldehyde crosslinking agent, an alcohol crosslinking agent, an imine crosslinking agent or an alkane crosslinking agent. It is selected from one or more of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 1,2-ethylenediamine, 4,4'-diaminodiphenyl ether and dimethyl glutarate (DMS). EDC is preferred, and the volume percentage concentration is 2 to 30%. Preferably 5 to 20%, more preferably 8 to 15%.
[0021] Furthermore, the second cross-linking agent can be an aldehyde cross-linking agent, an alcohol cross-linking agent, an imine cross-linking agent or an alkane cross-linking agent. Preferably, N-hydroxy-succinic acid imide (NHS) forms an imine cross-linking agent mixture with the EDC added in the previous step, and the role of the imine cross-linking agent mixture is the amide reaction of the amine group and the carboxyl group. The molar ratio of EDC to NHS is not particularly limited, preferably 1:1, 2:1, 6:1 and 5:2, more preferably 2:1, 6:1 and 5:2, and finally 6:1 is selected. There is no special restriction on the reaction concentration quotient, as long as the cross-linking reaction of the amine group and the carboxyl group can be carried out between the collagen molecules and / or within the molecule.
[0022] Furthermore, the cross-linking reaction of the imine cross-linking agent used is a covalent cross-linking reaction between amine groups and carboxyl groups. Therefore, the imine cross-linking agent can cause cross-linking reactions between amine groups and carboxyl groups in collagen molecules and / or within the molecules.
[0023] Furthermore, in step 1, the concentration of the recombinant collagen is 20 to 40 mg / mL.
[0024] Furthermore, the pH of the total reaction system of the preparation method is 3-6, preferably 3-4, more preferably 3, 3.5. The reaction temperature is 4-30°C, preferably 4-25°C, more preferably 18-23°C.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] The present invention provides a recombinant collagen-hyaluronic acid complex with a triple helix structure and a preparation method thereof, aiming to solve the problems that hyaluronic acid and collagen are easily degraded as natural materials, have a short retention time in the body, and have biological toxicity. The recombinant collagen-hyaluronic acid complex prepared by the present invention can significantly improve the moisture of the skin, repair damaged tissues, and enhance the natural elasticity of the skin. The complex not only optimizes its biocompatibility and stability, has excellent mechanical properties, but also significantly slows down the degradation rate in the body, thereby prolonging its effective action time in the skin, and is suitable for supporting materials in the field of medical cosmetology. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The electrophoresis results of the purification of recombinant collagen.
[0028] Figure 2 Schematic diagram of the recombinant collagen-hyaluronic acid complex obtained in Examples 2 to 5. DETAILED DESCRIPTION
[0029] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0030] The specific implementation of the present invention is described in detail below in conjunction with specific embodiments.
[0031] Example 1: Preparation of recombinant collagen using CHO cell expression system;
[0032] 1-1. Construction of recombinant collagen gene vector: Recombinant collagen is an optimized recombinant human type III collagen. The amino acid sequence of recombinant collagen obtained by algorithm design and optimization screening is as follows:
[0033]
[0034] 1-2. Construction of engineered cells: The plasmid containing the target gene is transfected into the host cell (CHO-K1) by electroporation, and the cell pool is screened after being cultured in an incubator to obtain candidate pool cells for subsequent collagen preparation.
[0035] 1-3. Preparation of collagen: The recombinant CHO cells were cultured and expanded in shake flasks, and collagen was expressed in large quantities in a fermenter. The protein expression level in the fermentation supernatant was determined using SDS-PAGE electrophoresis.
[0036] (1) When the cells cultured in the fermenter reach the expected density, stop the culture, collect the cell culture fluid and centrifuge to collect the supernatant.
[0037] (2) Use SDS-PAGE electrophoresis to detect the purity and impurities of the centrifuged samples.
[0038] (3) The fermentation broth supernatant was filtered through a 0.22 μm filter membrane, and the fermentation broth was purified using MMC composite filler column chromatography and 4FF filler molecular sieve chromatography. The sample was concentrated using a concentrator tube and the sample concentration was quantitatively analyzed using BCA quantification.
[0039] (4) Sample freeze-drying and storage: The concentrated and quantified recombinant collagen is subjected to a freeze-drying procedure. The sample is placed in a freeze-drying bottle and frozen at 40°C for 4 hours. The pre-frozen sample is placed in a freeze dryer at a temperature of -50 to -80°C and a vacuum degree of 10 to 20 Pa for preliminary drying for 24 to 48 hours. After the preliminary drying is completed, the temperature of the freeze-drying chamber is gradually increased to 20 to 25°C, and the vacuum degree is maintained unchanged for 12 to 24 hours to remove residual moisture. After completion, the pressure of the freeze-drying chamber is slowly restored, the freeze-drying bottle is taken out, and it is immediately sealed with a sealing cap to prevent the sample from absorbing moisture. The freeze-dried sample is placed in a dry sealed container and can be stored in a low temperature environment of -20°C or -80°C to ensure the long-term stability and activity of the sample.
[0040] 1-4. Characterization of recombinant collagen: Denaturing non-reducing SDS-PAGE was performed on the recombinant collagen sample to detect the trimer assembly. The results are as follows: Figure 1 As shown, lanes 1 to 5 are eluted samples during the purification process, and lane 6 is the purified recombinant collagen. It can be seen that the recombinant collagen in lane 6 has a higher purity, and most of the remaining impurities are eluted and recombined.
[0041] Example 2: Preparation of recombinant collagen-hyaluronic acid complex;
[0042] 2-1. Preparation of reaction system buffer: MES was fully dissolved in water for injection at 100 mM, pH 3.5, and sterilized by filtration through a 0.22 μm filter membrane before subsequent use.
[0043] 2-2. Preparation of recombinant collagen: Dissolve the above recombinant collagen at 35 mg / mL in 100 mM, pH 3.5 MES buffer until the protein is completely dissolved to form a homogeneous and clear solution.
[0044] 2-3. First cross-linking reaction: EDC was fully dissolved in 100 mM MES solution (pH 3.5) at 400 mM, and used as the first cross-linking agent to cross-link with the 35 mg / mL recombinant collagen solution in step 2-2. The cross-linking time was not less than 30 minutes. After the cross-linking reaction was completed, the cross-linked recombinant type III collagen fibers formed by the first cross-linking reaction were collected by centrifugation.
[0045] 2-4. Second cross-linking reaction: NHS is added to the solution of step 2-3 to form an imine cross-linking agent mixture with EDC (the molar ratio of EDC to NHS is 6:1) to activate the carboxyl groups in the reaction. After the cross-linking reaction is completed, the cross-linked recombinant type III collagen fibers formed by the second cross-linking reaction are collected by centrifugation.
[0046] 2-5. Recombinant collagen-bioscaffold cross-linking: Add γ-PGA twice the amount of recombinant collagen to the cross-linking system of step 2-4 to provide carboxyl groups as a scaffold for cross-linking with the solution, and collect the recombinant collagen-bioscaffold cross-linked complex by centrifugation.
[0047] 2-6. Adding hyaluronic acid: Add 35 mg / mL of hyaluronic acid to the recombinant collagen-bioscaffold cross-linked complex solution of step 2-5, and perform cross-linking in an acidic buffer solution at pH 3.5 for not less than 30 minutes to form a recombinant collagen-hyaluronic acid complex.
[0048] 2-7. Clean impurities and unreacted cross-linking agent: Wash 3 times with injection water or normal saline at a 10-fold volume ratio.
[0049] 2-8. Freeze drying: Place the sample in a freeze drying bottle and freeze it at 40°C for 4 hours. Place the pre-frozen sample in a freeze dryer for preliminary drying for 24 to 48 hours. After the preliminary drying is completed, gradually increase the temperature of the freeze drying chamber and maintain the vacuum degree unchanged for 12 to 24 hours to remove residual moisture. After completion, place the freeze-dried sample in a dry sealed container and store it in a low temperature environment.
[0050] Example 3, Preparation of recombinant collagen-hyaluronic acid complex;
[0051] 3-1. Preparation of reaction system buffer: the same as step 2-1 of Example 1.
[0052] 3-2. Preparation of recombinant collagen: Dissolve the above recombinant collagen at 35 mg / mL in 100 mM, pH 3.5 MES buffer until the protein is completely dissolved to form a homogeneous and clear solution.
[0053] 3-3. First cross-linking reaction: EDC was fully dissolved in 100 mM MES solution (pH 3.5) at 600 mM, and used as the first cross-linking agent to cross-link with the 35 mg / mL recombinant collagen solution in 3-2. The cross-linking time was not less than 30 minutes. After the cross-linking reaction was completed, the cross-linked recombinant type III collagen fibers formed by the first cross-linking reaction were collected by centrifugation.
[0054] 3-4. Second cross-linking reaction: NHS is added to the solution of step 3-3 to form an imine cross-linking agent mixture with EDC (the molar ratio of EDC to NHS is 2:1) to activate the carboxyl groups in the reaction. After the cross-linking reaction is completed, the cross-linked recombinant type III collagen fibers formed by the second cross-linking reaction are collected by centrifugation.
[0055] 3-5. Recombinant collagen-bioscaffold cross-linking: Add γ-PGA with a content ten times that of recombinant collagen to the cross-linking system of step 3-4 to provide carboxyl groups as a scaffold for cross-linking with the solution, and collect the recombinant collagen-bioscaffold cross-linked complex by centrifugation.
[0056] 3-6. Adding hyaluronic acid: Add 35 mg / mL hyaluronic acid to the recombinant collagen-bioscaffold cross-linked complex solution of step 3-5, and perform cross-linking in an acidic buffer solution at pH 3.5 for not less than 30 minutes to form a recombinant collagen-hyaluronic acid complex.
[0057] 3-7. Clean impurities and unreacted cross-linking agent: Wash three times with 10 mM phosphate buffer solution at a 10-fold volume ratio.
[0058] 3-8. Freeze drying: Place the sample in a freeze drying bottle and freeze it at 40°C for 4 hours. Place the pre-frozen sample in a freeze dryer for preliminary drying for 24 to 48 hours. After the preliminary drying is completed, gradually increase the temperature of the freeze drying chamber and maintain the vacuum degree unchanged for 12 to 24 hours to remove residual moisture. After completion, place the freeze-dried sample in a dry sealed container and store it in a low temperature environment.
[0059] Example 4: Preparation of recombinant collagen-hyaluronic acid complex;
[0060] 4-1. Preparation of reaction system buffer: the same as step 2-1 of Example 1.
[0061] 4-2. Preparation of recombinant collagen: Dissolve the above recombinant collagen at 35 mg / mL in the buffer prepared in step 4-1 until the protein is completely dissolved to form a uniform and clear solution.
[0062] 4-3. Recombinant collagen cross-linking reaction: Glutaraldehyde is used as a cross-linking agent at a reaction concentration of 30-40 ppm to cross-link the solution in step 4-2 for a cross-linking time of not less than 30 minutes, and the cross-linked recombinant collagen fibers are collected by centrifugation.
[0063] 4-4. Recombinant collagen-bioscaffold cross-linking: Add γ-PGA with the same content as recombinant collagen to the cross-linking system in step 4-3 to provide carboxyl groups as a scaffold for cross-linking with the solution, and collect the recombinant collagen-bioscaffold cross-linked complex by centrifugation.
[0064] 4-5. Adding hyaluronic acid: Add 35 mg / mL hyaluronic acid to the recombinant collagen-bioscaffold cross-linked complex solution of step 4-4, and perform cross-linking in an acidic buffer solution at pH 3.5 for not less than 30 minutes to form a recombinant collagen-hyaluronic acid complex.
[0065] 4-6. Clean impurities and unreacted cross-linking agent: Wash 3 times with injection water or normal saline at a 10-fold volume ratio.
[0066] 4-7. Freeze drying: Place the sample in a freeze drying bottle and freeze it at 40°C for 4 hours. Place the pre-frozen sample in a freeze dryer for preliminary drying for 24 to 48 hours. After the preliminary drying is completed, gradually increase the temperature of the freeze drying chamber and maintain the vacuum degree unchanged for 12 to 24 hours to remove residual moisture. After completion, place the freeze-dried sample in a dry sealed container and store it in a low temperature environment.
[0067] Example 5, Preparation of recombinant collagen-hyaluronic acid complex;
[0068] 5-1. Preparation of reaction system buffer: the same as step 2-1 of Example 1.
[0069] 5-2. Preparation of recombinant collagen: Dissolve the above recombinant collagen at 35 mg / mL in the buffer prepared in step 5-1 until the protein is completely dissolved to form a uniform and clear solution.
[0070] 5-3. First cross-linking reaction: Glutaraldehyde is used as a cross-linking agent at a reaction concentration of 35 ppm and cross-linked with the 35 mg / mL recombinant collagen solution of step 5-2 for a cross-linking time of not less than 16 hours to perform a covalent cross-linking reaction between the collagen molecules and / or between the amino groups within the molecules. After the cross-linking reaction is completed, the cross-linked collagen fibers formed by the first cross-linking reaction are collected by centrifugation.
[0071] 5-4. Second cross-linking reaction: EDC and NHS are mixed to form an imine cross-linking agent mixture of the second cross-linking agent (EDC / NHS), which is added to the single cross-linked collagen fiber solution of step 5-3.
[0072] 5-5. Add hyaluronic acid: add 35 mg / mL hyaluronic acid to the solution of 5-4 and perform cross-linking in an acidic buffer solution of pH 3.5 for 4 hours.
[0073] 5-6. Cleaning impurities and unreacted cross-linking agent: Washing three times with 10 mM phosphate buffer solution at a 10-fold volume ratio to form the recombinant collagen-hyaluronic acid complex of the present invention.
[0074] 5-7. Freeze drying: Place the sample in a freeze drying bottle and freeze it at 40°C for 4 hours. Place the pre-frozen sample in a freeze dryer for preliminary drying for 24 to 48 hours. After the preliminary drying is completed, gradually increase the temperature of the freeze drying chamber and maintain the vacuum degree unchanged for 12 to 24 hours to remove residual moisture. After completion, place the freeze-dried sample in a dry sealed container and store it in a low temperature environment.
[0075] Example 6: Performance test of recombinant collagen-hyaluronic acid complex;
[0076] 6-1. Mechanical properties test: The elastic modulus and compressive strength of the cross-linked recombinant collagen-hyaluronic acid complex are tested to ensure that its mechanical properties meet the application requirements and have supporting functions. Use a DHR rheometer to perform rheological analysis and viscosity analysis of the recombinant collagen-hyaluronic acid complex. For rheological analysis, the angular frequency (ω) of the test varies between 100 and 0.1 rad / s, and the initial strain (γ) is set to 0.01%. Figure 2 The test sample examples of Examples 2 to 5 are shown. It can be seen that the samples of the four examples are all in a translucent non-flowing solid state. The product using the EDC / NHS mixture as a cross-linking agent has the same rheological properties as the product cross-linked using the commonly used cross-linking agent glutaraldehyde, which proves that cross-linking using the EDC / NHS mixture as a cross-linking agent and glutaraldehyde as a cross-linking agent can produce similar results. At the same time, when the EDC / NHS mixture is used as a cross-linking agent, there is no need to wash to remove excess toxic glutaraldehyde, and no other chemical substances are introduced.
[0077] 6-2. Stability test: Under different temperature and humidity conditions, the stability of the recombinant collagen-hyaluronic acid complex was tested to evaluate its degradation during storage and use. The recombinant collagen-hyaluronic acid complex in Examples 2 to 5 was divided into sterile centrifuge tubes and sealed, and treated at different times and temperatures for accelerated stability testing and long-term stability testing. Weigh 10g of recombinant collagen-hyaluronic acid complex freeze-dried sample, soak it in 100mL of PBS with a collagenase content of 12.5U / mL, and digest it in a constant temperature incubator at 37°C for 7 days. Filter to remove the solution, wash with deionized water 3 times, weigh it after freeze drying, use a DHR rheometer to detect the mechanical properties and calculate the degradation rate, and determine the stability of the protein based on the changes in mechanical properties. The results are shown in Tables 1 and 2.
[0078] Table 1 Accelerated stability test results of recombinant collagen-hyaluronic acid complex (%)
[0079] sample High temperature 6 hours Room temperature 1 day 2 days at room temperature Room temperature for one week Example 2 0.3 0.5 0.9 1.5 Example 3 2.7 4.5 6.1 8.4 Example 4 5.3 7.4 9.5 11.3 Example 5 1.3 2.6 3.4 5.0
[0080] Table 2 Recombinant collagen-hyaluronic acid complex stability test results (%)
[0081]
[0082]
[0083] As can be seen from Table 1 and Table 2, the recombinant collagen-hyaluronic acid complex prepared by the present invention exhibits exceptionally excellent stability. The test results show that the recombinant collagen-hyaluronic acid complex in Example 2 is stable for at least 6 months, 12 months, 18 months and 24 months, and can still maintain a degradation rate of less than or equal to 3.0% in the 24th month; while the remaining embodiments all showed varying degrees of degradation, among which Examples 3 and 4 showed a degradation of more than 15.0% at the 24th month. From the above degradation results, it can be seen that the product of the cross-linking of collagen and hyaluronic acid using a suitable bioscaffold material and an EDC / NHS mixture in the present invention has better mechanical properties than the glutaraldehyde cross-linking product, and no new chemical substances are added, it has higher biocompatibility and does not produce potential toxicity.
[0084] In summary, the present invention provides a recombinant collagen-hyaluronic acid complex with a triple helix structure and a preparation method thereof, aiming to solve the problems that hyaluronic acid and collagen are easily degraded as natural materials, have a short retention time in the body, and have biological toxicity. The recombinant collagen-hyaluronic acid complex prepared by the present invention can significantly improve the moisture of the skin, repair damaged tissues, and enhance the natural elasticity of the skin. The complex not only optimizes its biocompatibility and stability, has excellent mechanical properties, but also significantly slows down the degradation rate in the body, thereby prolonging its effective action time in the skin, and is suitable for supporting materials in the field of medical cosmetology.
[0085] The above are only preferred embodiments of the present invention. It should be pointed out that, for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention. These should also be regarded as the protection scope of the present invention. These will not affect the effect of the implementation of the present invention and the practicality of the patent.
Claims
1. A recombinant collagen-hyaluronic acid complex, characterized in that: The recombinant collagen has a triple helix structure, and the hyaluronic acid is coupled with the recombinant collagen through a covalent bond to form a complex.
2. The recombinant collagen-hyaluronic acid complex according to claim 1, characterized in that: The recombinant collagen is an optimized recombinant human type III collagen, and the amino acid sequence of the recombinant collagen is shown in SEQ ID No.
1.
3. The recombinant collagen-hyaluronic acid complex according to claim 1, characterized in that: The components of the recombinant collagen-hyaluronic acid complex include γ-PGA with a molecular weight of 700 kDa.
4. Use of the recombinant collagen-hyaluronic acid complex according to any one of claims 1 to 3 in the preparation of tissue engineering materials.
5. A method for preparing the recombinant collagen-hyaluronic acid complex according to any one of claims 1 to 3, characterized in that: The following steps are involved: Step 1: dissolving the recombinant collagen in 10-100 mM MES buffer prepared with water for injection, and adding γ-PGA to the solution to form a first composite system; Step 2: mixing the first composite system with the first cross-linking agent to form a first cross-linking system; Step 3: mixing the first cross-linking system with the second cross-linking agent to obtain a collagen-scaffold cross-linking system; The second cross-linking agent is different from the first cross-linking agent; Step 4: Mixing hyaluronic acid with the collagen-scaffold cross-linking system to obtain a recombinant collagen-hyaluronic acid complex.
6. The preparation method according to claim 5, characterized in that: In step 1, the concentration of the recombinant collagen is 20-40 mg / mL.
7. The preparation method according to claim 5, characterized in that: The pH of the total reaction system of the preparation method is 3-6, and the reaction temperature is 4-30°C.
8. The preparation method according to claim 5, characterized in that: The first cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
9. The preparation method according to claim 8, characterized in that: The second cross-linking agent is N-hydroxy-succinic acid amide, and the molar ratio of the 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide to N-hydroxy-succinic acid amide is 6:1.
Citation Information
Patent Citations
Methods of forming ionically cross-linked gels
CN108884229A
Recombinant collagen composite injection and preparation method thereof
CN114146223A
Composite solution with combined application of recombinant III-type humanized collagen and hyaluronic acid and preparation process of composite solution
CN114796011A
Recombinant III-type humanized collagen and application thereof
CN116987176A
Medical gel dressing and preparation method thereof
CN117731829A
